“Interest expense for the three months ended March 31, 2026 decreased primarily due to lower variable interest rates on our credit facilities and reduced interest expense as a result of the settlement of the Convertible Senior Notes.”10-Q · May 8, 2026 ↗
Artivion, Inc.
AORT
Market read
Artivion, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 16 directly disclosed connections are confirming.
- AORT's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AORT's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 16 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- AORT's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +13.6% year over year.
- Net margin changed +5.7 percentage points in the latest annual period.
- Operating cash flow covered net income at 4.08x in the latest annual period.
- Foreign exchange has repeated favorable evidence across 3 filings.
- Operating margin changed -2.4 percentage points in the latest annual period.
- Diluted shares increased 13.2% in the latest annual period.
- Credit and interest rates has repeated adverse evidence across 4 filings.
- P/E is 141% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 64% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
24.61Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Seasonality Historically, we believe the demand for most of our aortic stent grafts is seasonal, with a decline in demand generally occurring in the third quarter primarily due to the summer holiday season in Europe.”10-Q · May 8, 2026 ↗
“Gross margin as a percentage of total revenues was positively impacted by a favorable product mix and favorable pricing of certain products and tissues shipped, partially offset by unfavorable costs of certain products shipped during the three months ended Ma…”10-Q · May 8, 2026 ↗
“27 Table of Contents The increase in gross margin for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025, was primarily due to a favorable mix of certain products and tissues shipped, an increase in the average sales p…”10-Q · May 8, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.6× · EV/sales 3.0×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for AORT. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for AORT. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind AORT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BAXBaxter International Inc.supplierFeb 18, 2026 ▾
“We began to manufacture and supply PerClot ® hemostatic powder (“PerClot”) during the second quarter of 2023 (as part of our Transitional Manufacturing and Supply Agreement with Baxter International, Inc.).”
ABTAbbott LaboratoriescompetitorMay 8, 2026 ▾
“On-X heart valves compete primarily with mechanical valves from Abbott Laboratories, Medtronic, plc.”
Depended on by
LMATLeMaitre Vascular, Inc.competitorFeb 26, 2026 ▾
“Notable larger competitors include Abbott; Baxter; Artivion; Becton Dickinson; Edwards Lifesciences; Getinge; LifeNet Health; Terumo; and W.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 15 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AORT is currently a Early Follower in the organic co-movement group Healthcare Real Estate. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AORT; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.